AcelRx Pharma Plans to Resubmit New Drug Application for Dsuvia Post author:Sam Post published:March 8, 2018 Post category:BioPharma AcelRx Pharmaceuticals plans to resubmit the NDA for Dsuvia in the second quarter of this year. Source: BioSpace You Might Also Like Ionis and Roche Tout Positive Data in Early-Stage Huntington’s Disease Trial March 1, 2018 Human Longevity Co-Founder To Helm Newly Launched Sorrento Spinoff June 12, 2017 New Jersey Implant Maker Braeburn Pharma Yanks Plans for $150 Million IPO February 2, 2017